Ionis topped third-quarter revenue estimates with roughly $243 million in sales, yet IONS shareholders took losses as the same report showed a $110 million net loss and a more than 50% cut to TRYNGOLZA guidance.

NEW YORK, Nov. 10, 2026 /PRNewswire/ — A revenue beat did not stop the losses: Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares fell sharply on November 9, 2026, after the Company cut its full-year TRYNGOLZA product sales guidance from $100-$110 million to approximately $50 million. If you bought IONS before today’s report and are now sitting on a loss, you may have legal rights. IONS investors who lost money are encouraged to submit their loss information now . You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com  or by telephone at (888) SueWallSt.

Ionis beat Wall Street estimates on both revenue and EPS. Third-quarter revenue came in at approximately $243 million, up about 55% year over year. The same report showed a $110 million net loss for the quarter. Nine-month losses reached approximately $317 million.

Ionis stated that commercial revenue rose 18% for the quarter and 23% for the first nine months of 2026, “primarily driven by DAWNZERA product sales.” Conversely, TRYNGOLZA was experiencing “a more gradual ramp” than management had planned for. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of IONS investors who suffered losses.

Down on your IONS shares after today’s report? Start your free IONS loss review or call (888) SueWallSt.

WHY SUEWALLST : SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured billions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the IONS Investigation

Q: How much did IONS stock drop?  A: IONS shares fell roughly $7.27, or about 18.44% to open at approximately $32.15 on November 9, 2026, after the Company disclosed that it had cut its full-year 2026 TRYNGOLZA product sales guidance by roughly 50%, from $100-$110 million to approximately $50 million. By midday the stock had fallen more than 25% from the November 6 closing price. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Which statements are being investigated as potentially misleading?  A: The investigation concerns whether Ionis Pharmaceuticals, Inc. made materially false or misleading statements regarding its full-year 2026 TRYNGOLZA product sales outlook. When the Company disclosed on November 9, 2026 that it had lowered that guidance to approximately $50 million, the stock price declined sharply.

Q: When did Ionis Pharmaceuticals allegedly mislead investors? A: The investigation concerns statements made before the November 9, 2026 corrective disclosure that allegedly caused investors to purchase IONS securities at inflated prices.

Q: What do IONS investors need to do right now?  A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?  A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my IONS shares — can I still recover losses?  A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought IONS and sold at a loss may still participate in the investigation.

Q: What if my IONS losses are small — is it still worth contacting a lawyer?  A: Yes. There is no minimum loss amount required to participate in the investigation.

Q: What does it cost me to participate?  A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com 
Tel: (888) SueWallSt
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals-302934837.html

SOURCE SueWallSt.com